Korean company behind retina-based CVD risk AI plans to go public
Mediwhale, a medical AI startup in South Korea, has recently raised 20 billion won ($13 million) in a Series C funding round led by Seoul-based private equity firm, Premier Partners. KB Investment, Quad Asset Management, IMM Investment, Hana Ventures, AON Investment, and Startup Partners also joined the round. This brings its total investments raised to date to 51.2 billion won ($34 million).
Photo: Ksenia Chernaya/Pexels
Mediwhale, a medical AI startup in South Korea, has recently raised 20 billion won ($13 million) in a Series C funding round led by Seoul-based private equity firm, Premier Partners.
KB Investment, Quad Asset Management, IMM Investment, Hana Ventures, AON Investment, and Startup Partners also joined the round.
This brings its total investments raised to date to 51.2 billion won ($34 million).
Founded in 2016, the company develops AI-powered software that analyses retinal images to predict the risk of cardiovascular disease and chronic kidney disease, and screens for eye conditions such as glaucoma, cataracts, and diabetic retinopathy.
Its flagship product, Dr Noon CVD, which the company claims has shown comparable accuracy to conventional cardiac CT, is currently used in over 170 hospitals worldwide, including those under the Yonsei University Health System.
WHAT'S IT FOR
In a media release, Mediwhale said its fresh funds will be used to conduct clinical trials and pursue regulatory approvals in the United States and other global markets.
The company is seeking De Novo approval from the US Food and Drug Administration for its CVD-specific AI software. It also plans to conduct proof-of-concept projects, particularly with primary care institutions, to generate case studies.
"The company's strategy is to simultaneously meet global regulatory standards and market demands by concentrating its capabilities on proving clinical efficacy and applicability in actual medical settings, which are key gateways to entering the US market," it explained.
Additionally, its Series C proceeds will fund its preparations to go public via a technology special listing on the KOSDAQ in the first half of 2027.
THE LARGER TREND
Korean medical AI companies continue to attract investments as they work towards global expansion. Earlier in February, Vuno secured 10 billion won ($6.9 million) in funding through perpetual convertible bonds. Late last year, AITRICS bagged 35 billion won ($24 million) in Series C funding to develop its AI products further.
Tags:
MobiHealthNews
https://www.mobihealthnews.com/news/asia/korean-company-behind-retina-based-cvd-risk-ai-plans-go-publicSign in to highlight and annotate this article
Conversation starters
Daily AI Digest
Get the top 5 AI stories delivered to your inbox every morning.
More about
startupcompanyfunding
Big Tech firms are accelerating AI investments and integration, while regulators and companies focus on safety and responsible adoption.
The AI landscape is experiencing unprecedented growth and transformation. This post delves into the key developments shaping the future of artificial intelligence, from massive industry investments to critical safety considerations and integration into core development processes. Key Areas Explored: Record-Breaking Investments: Major tech firms are committing billions to AI infrastructure, signaling a significant acceleration in the field. AI in Software Development: We examine how companies are leveraging AI for code generation and the implications for engineering workflows. Safety and Responsibility: The increasing focus on ethical AI development and protecting vulnerable users, particularly minors. Market Dynamics: How AI is influencing stock performance, cloud computing strategies, and
Is Your Website Blocking AI Crawlers? Check with This Free Robots.txt Analyzer
AI Bots Are Everywhere Now GPTBot, ClaudeBot, Applebot — every major AI company now has a web crawler. And websites are scrambling to block them. But how do you know if YOUR robots.txt is actually working? Most robots.txt checkers only test Googlebot. They don't tell you if GPTBot is blocked, or if your Allow/Disallow rules have priority conflicts. What I Built Robots.txt Checker — a free tool that: Fetches any site's robots.txt and parses every rule Tests specific paths against specific user-agents Supports AI bot testing — GPTBot, ChatGPT-User, ClaudeBot built into the dropdown Shows sitemaps found in the file Displays raw content for manual inspection Try It: Check google.com Paste google.com and you'll see: 4 user-agent groups with dozens of Disallow rules Sitemap references Which path
Knowledge Map
Connected Articles — Knowledge Graph
This article is connected to other articles through shared AI topics and tags.
More in Market News
Big Tech firms are accelerating AI investments and integration, while regulators and companies focus on safety and responsible adoption.
The AI landscape is experiencing unprecedented growth and transformation. This post delves into the key developments shaping the future of artificial intelligence, from massive industry investments to critical safety considerations and integration into core development processes. Key Areas Explored: Record-Breaking Investments: Major tech firms are committing billions to AI infrastructure, signaling a significant acceleration in the field. AI in Software Development: We examine how companies are leveraging AI for code generation and the implications for engineering workflows. Safety and Responsibility: The increasing focus on ethical AI development and protecting vulnerable users, particularly minors. Market Dynamics: How AI is influencing stock performance, cloud computing strategies, and
Discussion
Sign in to join the discussion
No comments yet — be the first to share your thoughts!